DNA

Preliminary results for the year ended 31 December 2024Preliminary results for the year ended 31 December 2024

Preliminary results for the year ended 31 December 2024

~ Strong commercial momentum underpins transformative financial performance ~ Strong 2024 financial performance in line with guidance Revenue growth of…

1 month ago
ALIGNMT.AI Launches AI Governance Platform to Safeguard Healthcare AI Adoption and Reduce Compliance RiskALIGNMT.AI Launches AI Governance Platform to Safeguard Healthcare AI Adoption and Reduce Compliance Risk

ALIGNMT.AI Launches AI Governance Platform to Safeguard Healthcare AI Adoption and Reduce Compliance Risk

With AI adoption in healthcare projected to surpass $614 billion by 2034, ALIGNMT.AI delivers real-time oversight to mitigate financial, legal,…

1 month ago
Wave’s Reflect Launch Defines New Era of AI-Supported Mental Health CareWave’s Reflect Launch Defines New Era of AI-Supported Mental Health Care

Wave’s Reflect Launch Defines New Era of AI-Supported Mental Health Care

Combining structured, native, end-to-end data, a large and engaged user base and deep mental health domain expertise, Wave's AI product…

1 month ago
Freenome Names Aaron Elliott, Ph.D., as Chief Executive Officer to Lead the Company’s Next Chapter of Commercial Growth and Product InnovationFreenome Names Aaron Elliott, Ph.D., as Chief Executive Officer to Lead the Company’s Next Chapter of Commercial Growth and Product Innovation

Freenome Names Aaron Elliott, Ph.D., as Chief Executive Officer to Lead the Company’s Next Chapter of Commercial Growth and Product Innovation

Accomplished industry leader brings specialized experience to advance Freenome's screening blood tests for colorectal cancer, lung cancer and additional indications…

1 month ago
Defence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer TherapiesDefence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer Therapies

Defence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer Therapies

Montreal, Quebec--(Newsfile Corp. - April 8, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"),…

1 month ago
European Commission approves subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancerEuropean Commission approves subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer

European Commission approves subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer

Subcutaneous (SC) amivantamab offers patients greater convenience, reducing administration time from hours to minutes and with a five-fold reduction in…

1 month ago
BREAKTHROUGH PRIZE ANNOUNCES 2025 LAUREATES IN LIFE SCIENCES, FUNDAMENTAL PHYSICS, AND MATHEMATICSBREAKTHROUGH PRIZE ANNOUNCES 2025 LAUREATES IN LIFE SCIENCES, FUNDAMENTAL PHYSICS, AND MATHEMATICS

BREAKTHROUGH PRIZE ANNOUNCES 2025 LAUREATES IN LIFE SCIENCES, FUNDAMENTAL PHYSICS, AND MATHEMATICS

"Oscars® of Science" Awards Six $3 Million Prizes GLP-1 Diabetes and Obesity Discovery | Multiple Sclerosis Causes and Treatments | DNA…

1 month ago
Breakthrough Prize Foundation Announces Student Winner of 10th Annual Breakthrough Junior Challenge Science Video CompetitionBreakthrough Prize Foundation Announces Student Winner of 10th Annual Breakthrough Junior Challenge Science Video Competition

Breakthrough Prize Foundation Announces Student Winner of 10th Annual Breakthrough Junior Challenge Science Video Competition

Jasmine Eyal, Age 16, of Singapore, Receives Top Honors and $400,000 in Education Prizes for her Original Video Explaining Mechanogenetic…

1 month ago
Global Cancer Research Community Gathers to Share Breakthroughs at The Mark Foundation’s 2025 Scientific SymposiumGlobal Cancer Research Community Gathers to Share Breakthroughs at The Mark Foundation’s 2025 Scientific Symposium

Global Cancer Research Community Gathers to Share Breakthroughs at The Mark Foundation’s 2025 Scientific Symposium

NEW YORK, April 3, 2025 /PRNewswire/ -- The Mark Foundation for Cancer Research convened more than 150 scientists from 13 states…

1 month ago
Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the KneePacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

-- Novel, locally administered gene therapy designed to boost cellular production of anti-inflammatory protein IL-1Ra in the knee -- --…

1 month ago